50% Off! Beat the market in 2025 with InvestingProCLAIM SALE

Hemogenyx Pharmaceuticals shareholders approve share restructure

Published 12/09/2024, 08:32 AM

LONDON - Hemogenyx Pharmaceuticals plc announced today that its shareholders have approved all resolutions during an Extraordinary General Meeting (EGM), including the restructuring of the company's share capital. The EGM, which took place earlier today, saw a significant majority of votes cast in favor of the proposed resolutions.

The company's proxy voting results revealed strong shareholder support, with over 95% of votes in favor of both the subdivision and reclassification of existing ordinary shares and the consolidation of the New Ordinary Shares. Additionally, over 92% of votes supported granting the directors authority to allot and issue shares.

Specifically, the first resolution to reclassify existing ordinary shares received 95.39% votes in favor, while the second resolution regarding the consolidation of New Ordinary Shares garnered 95.41% approval. The third resolution, which grants authority to issue shares, was supported by 92.24% of votes.

A special resolution to adopt new articles of association was also passed with 94.80% of the votes. Furthermore, the statutory rights of pre-emption were dis-applied for the allotment of equity securities for cash with 92.78% approval.

The total votes cast represented 38.74% to 38.79% of the company's issued share capital (ISC) as of December 5, 2024, the date when members were registered to be entitled to attend and vote at the meeting.

Votes withheld, which are not considered legal votes and are not counted in the calculation of votes for or against the resolutions, ranged from 1,494,053 to 12,167,035 across the different resolutions.

The resolutions passed at the EGM are expected to be made available for inspection at the National Storage Mechanism in due course. This announcement is based on a press release statement from Hemogenyx Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.